Prediction of trifluridine/tipiracil (TAS-102) effectiveness in patients with refractory metastatic colorectal cancer (mCRC): Real-life data from the Czech Republic.

被引：0
|
作者：
Grell, Peter
Dvorak, Josef
Vocka, Michal
John, Stanislav
Tuskova, Helena
Buchler, Tomas
Borilova, Simona
Selingerova, Iveta
Vyzula, Rostislav
Petruzelka, Lubos B.
Kiss, Igor
Obermannova, Radka
机构：
[1] Masaryk Mem Canc Inst, Brno, Czech Republic
[2] Charles Univ Med Sch & Teaching Hosp, Hradec Kralove, Czech Republic
[3] Charles Univ Prague, Prague, Czech Republic
[4] Dept Oncol & Radiotherapy, Hradec Kralove, Czech Republic
[5] Charles Univ Prague, Fac Med 1, Dept Oncol, Prague, Czech Republic
[6] Thomayer Univ Hosp, Prague, Czech Republic
[7] Masaryk Mem Canc Inst, Reg Ctr Appl Mol Oncol, Brno, Czech Republic
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.e15102
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15102
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Compassionate use program for trifluridine/tipiracil (TAS-102) in metastatic colorectal cancer: a real-life overview
    Salvatore, L.
    Niger, M.
    Bellu, L.
    Tamburini, E.
    Garcia-Alfonso, P.
    Amellal, N.
    Delmas, A-S.
    Wahba, M.
    Prager, G.
    ANNALS OF ONCOLOGY, 2016, 27
  • [2] Trifluridine/Tipiracil (TAS-102) in refractory metastatic colorectal cancer: Real-world data of 13 oncological centers in Portugal
    Tomas, T.
    Nogueira-Costa, G.
    Eriz, I.
    Vitorino, M.
    Baptista, M. Vaz
    Correia, M.
    Pereira, T.
    Oliveira, A.
    Leal da Costa, L.
    Pimenta, J.
    Liu, P.
    Peixeto, I.
    Luz, P.
    Gil, L.
    Silva, D.
    Caleca, T.
    Neves, M.
    Quintela, A.
    Monteiro, A.
    Atalaia, G.
    Silva, M.
    Fiuza, T.
    ANNALS OF ONCOLOGY, 2019, 30 : 88 - 88
  • [3] Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands
    Kwakman, Johannes J. M.
    Vink, G.
    Vestjens, J. H.
    Beerepoot, L. V.
    de Groot, J. W.
    Jansen, R. L.
    Opdam, F. L.
    Boot, H.
    Creemers, G. J.
    van Rooijen, J. M.
    Los, M.
    Vulink, A. J. E.
    Schut, H.
    van Meerten, E.
    Baars, A.
    Hamberg, P.
    Kapiteijn, E.
    Sommeijer, D. W.
    Punt, C. J. A.
    Koopman, M.
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2018, 23 (03) : 482 - 489
  • [4] Safety and efficacy of trifluridine/tipiracil (TAS-102) plus bevacizumab in clinical practice for patients with refractory metastatic colorectal cancer
    Kotani, D.
    Kuboki, Y.
    Yasuda, K.
    Nakamura, Y.
    Kawazoe, A.
    Bando, H.
    Taniguchi, H.
    Shitara, K.
    Yoshino, T.
    ANNALS OF ONCOLOGY, 2018, 29 : 34 - 34
  • [5] Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands
    Johannes J. M. Kwakman
    G. Vink
    J. H. Vestjens
    L. V. Beerepoot
    J. W. de Groot
    R. L. Jansen
    F. L. Opdam
    H. Boot
    G. J. Creemers
    J. M. van Rooijen
    M. Los
    A. J. E. Vulink
    H. Schut
    E. van Meerten
    A. Baars
    P. Hamberg
    E. Kapiteijn
    D. W. Sommeijer
    C. J. A. Punt
    M. Koopman
    International Journal of Clinical Oncology, 2018, 23 : 482 - 489
  • [6] Neutropenia as a predictor of efficacy in the treatment of metastatic colorectal cancer with TAS-102 (trifluridine - tipiracil).
    Rodriguez Garces, Maria Yeray
    Senin, Loreto Dominguez
    Urbano, Maria Amor
    Tarazona, Victoria Avino
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E15564 - E15564
  • [7] A systematic review of observational studies of trifluridine/tipiracil (TAS-102) for metastatic colorectal cancer
    Andersen, Stig E.
    Andersen, Ida B.
    Jensen, Benny V.
    Pfeiffer, Per
    Ota, Takayo
    Larsen, Jim S.
    ACTA ONCOLOGICA, 2019, 58 (08) : 1149 - 1157
  • [8] Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer
    Kotani, Daisuke
    Kuboki, Yasutoshi
    Horasawa, Satoshi
    Kaneko, Asumi
    Nakamura, Yoshiaki
    Kawazoe, Akihito
    Bando, Hideaki
    Taniguchi, Hiroya
    Shitara, Kohei
    Kojima, Takashi
    Tsuji, Akihito
    Yoshino, Takayuki
    BMC CANCER, 2019, 19 (01)
  • [9] Trifluridine/Tipiracil (TAS-102) for refractory metastatic colorectal cancer in clinical practice: a feasible alternative for patients with good performance status
    C. Carriles
    P. Jimenez-Fonseca
    M. Sánchez-Cánovas
    P. Pimentel
    A. Carmona-Bayonas
    T. García
    M. Carbajales-Álvarez
    A. Lozano-Blázquez
    Clinical and Translational Oncology, 2019, 21 : 1781 - 1785
  • [10] Trifluridine/Tipiracil (TAS-102) for refractory metastatic colorectal cancer in clinical practice: a feasible alternative for patients with good performance status
    Carriles, C.
    Jimenez-Fonseca, P.
    Sanchez-Canovas, M.
    Pimentel, P.
    Carmona-Bayonas, A.
    Garcia, T.
    Carbajales-Alvarez, M.
    Lozano-Blazquez, A.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2019, 21 (12): : 1781 - 1785
12345